176 related articles for article (PubMed ID: 16087205)
1. Facing the challenge: the symposium in context.
Widdus R
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S30-2. PubMed ID: 16087205
[No Abstract] [Full Text] [Related]
2. Public-private partnerships: an overview.
Widdus R
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S1-8. PubMed ID: 16085172
[TBL] [Abstract][Full Text] [Related]
3. Public-private partnership: from there to here.
Croft SL
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
[TBL] [Abstract][Full Text] [Related]
4. Public-private partnerships for health.
Ratzan SC
J Health Commun; 2007 Jun; 12(4):315-6. PubMed ID: 17558785
[No Abstract] [Full Text] [Related]
5. Public-private partnerships in drug development for underdeveloped countries: an interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division. Interview by Thomasine Kushner.
Wheeler C
Camb Q Healthc Ethics; 2003; 12(4):429-33. PubMed ID: 14619375
[No Abstract] [Full Text] [Related]
6. [Biomedical research: private interests and public interests].
Martin J
Sante Publique; 2001 Mar; 13(1):89-93. PubMed ID: 11525046
[No Abstract] [Full Text] [Related]
7. Public-private partnerships: new ways to discover, develop and deliver drugs for tropical diseases.
Hentschel CC
Southeast Asian J Trop Med Public Health; 2004; 35 Suppl 2():1-4. PubMed ID: 15906625
[No Abstract] [Full Text] [Related]
8. How to make global trade diminish poverty.
Lancet; 2002 Apr; 359(9315):1359. PubMed ID: 11978326
[No Abstract] [Full Text] [Related]
9. A new era of hope for the world's most neglected diseases.
The
PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
[TBL] [Abstract][Full Text] [Related]
10. Public sector seeks to bridge 'valley of death'.
Moran N
Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
[No Abstract] [Full Text] [Related]
11. Eurofile. Private-public drive to cut delays in drug development.
Mundell I
Eur J Cancer; 2008 Jan; 44(2):169. PubMed ID: 18335586
[No Abstract] [Full Text] [Related]
12. Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.
Hale VG; Woo K; Lipton HL
Health Aff (Millwood); 2005; 24(4):1057-63. PubMed ID: 16012146
[TBL] [Abstract][Full Text] [Related]
13. Biotech R&D still reeling.
Lawrence S
Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
[No Abstract] [Full Text] [Related]
14. Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines.
Nwaka S
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S20-9. PubMed ID: 16085175
[TBL] [Abstract][Full Text] [Related]
15. Creating conditions for greater private sector participation in achieving contraceptive security.
Sharma S; Dayaratna V
Health Policy; 2005 Mar; 71(3):347-57. PubMed ID: 15694501
[TBL] [Abstract][Full Text] [Related]
16. Uzbekistan drug airlift: a quantitative analysis of public/private collaboration.
Wertheimer AI; Santella TM; Arroyave VM
Pharm World Sci; 2005 Aug; 27(4):344-50. PubMed ID: 16228635
[TBL] [Abstract][Full Text] [Related]
17. The biotechnology revolution and world health.
Nossal SG
Public Health Rep; 1998; 113(2):122-7. PubMed ID: 9719812
[No Abstract] [Full Text] [Related]
18. [Does the public sector have an independent research role in the development of drugs?].
Poulsen HE; Grønlykke TB
Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
[TBL] [Abstract][Full Text] [Related]
19. Technological and social innovation: a unifying new paradigm for global health.
Gardner CA; Acharya T; Yach D
Health Aff (Millwood); 2007; 26(4):1052-61. PubMed ID: 17630448
[TBL] [Abstract][Full Text] [Related]
20. Global public-private partnerships against neglected diseases: building governance structures for effective outcomes.
Buckup S
Health Econ Policy Law; 2008 Jan; 3(Pt 1):31-50. PubMed ID: 18634631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
